Jump to content

INNA-051

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Gjs238 (talk | contribs) at 22:06, 25 December 2021 (WP:SUBCAT). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

INNA-051
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration		Intranasal
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]

References

  1. ^ "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
  2. ^ Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
Scholia has a profile for INNA-051 (Q110269792).


Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=INNA-051&oldid=1062045932"